Skip to main content
Fig. 4 | Molecular Medicine

Fig. 4

From: Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients

Fig. 4

Workflow for the identification of EGFR T790M in TKI progressed patients with advanced NSCLC. Procedures and timing of cfDNA EGFR testing from sample arrival is represented together with the decision algorithm suggested. *Patients resulting T790M negative after NGS analysis on cfDNA can undergone tumor biopsy, when feasible. Alternatively, the T790M negative patient can be retested on a second cfDNA after 2–4 weeks following the National Scientific Society recommendations on liquid biopsy (https://www.aiom.it/wp-content/uploads/2018/09/2018_biopsialiquida.pdf)

Back to article page